(4-((3,4-dichlorobenzyl)oxy)phenyl)methanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-((3,4-dichlorobenzyl)oxy)phenyl)methanamine
• 英文别名: [4-[(3,4-dichlorophenyl)methoxy]phenyl]methanamine
• 化学式: C₁₄H₁₃Cl₂NO
• 分子量: 282.169
• InChiKey: BBRKOBRIBVXCST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-((3,4-dichlorobenzyl)oxy)phenyl)methanamine 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 3.5h， 生成 6-chloro-3-(1-{4-[(3,4-dichlorobenzyl)oxy]benzyl}-4-(4-fluorophenyl)-1H-imidazol-5-yl)-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  1,4,5-Trisubstituted Imidazole-Based p53–MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers

  摘要：

  The tumor suppressor protein p53, the "guardian of the genome", is inactivated in nearly all cancer types by mutations in the TPS3 gene or by overexpression of its negative regulators, oncoproteins MDM2/MDMX. Recovery of p53 function by disrupting the p53-MDM2/MDMX interaction using small-molecule antagonists could provide an efficient nongenotoxic anticancer therapy. Here we present the syntheses, activities, and crystal structures of the p53-MDM2/MDMX inhibitors based on the 1,4,5-trisubstituted imidazole scaffold which are appended with aliphatic linkers that enable coupling to bioactive carriers. The compounds have favorable properties at both biochemical and cellular levels. The most effective compound 19 is a tight binder of MDM2 and activates p53 in cancer cells that express the wild-type p53, leading to cell cycle arrest and growth inhibition. Crystal structures reveal that compound 19 induces MDM2 dimerization via the aliphatic linker. This unique dimerization-binding mode opens new prospects for the optimization of the p53-MDM2/MDMX inhibitors and conjugation with bioactive carriers.

  DOI：

  10.1021/acs.jmedchem.7b00104
• 作为产物：
  描述：

  4-[(3,4-二氯苄基)氧基]苯甲醛 在 氨 、 氢气 作用下， 以 叔丁醇 为溶剂， 反应 15.0h， 以90%的产率得到(4-((3,4-dichlorobenzyl)oxy)phenyl)methanamine
  参考文献：
  名称：

  MOF 衍生的钴纳米粒子催化胺的一般合成

  摘要：

  MOF 为制造胺奠定了基础 还原胺化是化学家用来制造碳氮键的常用方法。该反应通常需要贵金属催化剂，将氨或其他胺与羰基化合物偶联，然后与氢气偶联。贾加迪什等人。报告了一类非贵重的钴纳米粒子，可在非常广泛的底物上催化这种反应，包括具有药用价值的复杂分子（参见 Chen 和 Xu 的观点）。钴首先嵌入金属有机框架 (MOF) 中，加热后转变为石墨壳。催化剂可以方便地从产品中分离出来，最多可循环使用六次。科学，这个问题 p。326; 另见第。304 由金属-有机骨架前体制备的钴纳米颗粒可催化非常广泛的还原胺化反应。用于合成药物相关化合物的贱金属催化剂的开发仍然是化学研究的一个重要目标。在这里，我们报告说，由石墨壳包裹的钴纳米颗粒是广泛有效的还原胺化催化剂。它们方便实用的制备需要在碳上模板组装钴-二胺-二羧酸金属有机骨架，然后在惰性气氛下热解。所得稳定且可重复使用的催化剂对于合成伯胺、仲胺、叔胺和 N-甲胺（超过

  DOI：

  10.1126/science.aan6245

文献信息

• Artificial Macrocycles as Potent p53–MDM2 Inhibitors
  作者：Natalia Estrada-Ortiz、Constantinos G. Neochoritis、Aleksandra Twarda-Clapa、Bogdan Musielak、Tad A. Holak、Alexander Dömling

  DOI：10.1021/acsmedchemlett.7b00219

  日期：2017.10.12

  Based on a combination of an Ugi four component reaction and a ring closing metathesis, a library of novel artificial macrocyclic inhibitors of the p53–MDM2 interaction was designed and synthesized. These macrocycles, alternatively to stapled peptides, target for the first time the large hydrophobic surface area formed by Tyr67, Gln72, His73, Val93, and Lys94 yielding derivatives with affinity to MDM2

  基于Ugi四组分反应和闭环易位的组合，设计并合成了新型的人工大环抑制剂p53–MDM2相互作用的文库。这些大环化合物，除装钉肽外，首次靶向由Tyr67，Gln72，His73，Val93和Lys94形成的大疏水表面积，从而产生对纳摩尔摩尔范围内的MDM2具有亲和力的衍生物。使用荧光偏振（FP）分析和1 H – 15 N二维HSQC核磁共振实验评估了它们与MDM2的结合亲和力。
• Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction
  作者：Constantinos G. Neochoritis、Jack Atmaj、Aleksandra Twarda-Clapa、Ewa Surmiak、Lukasz Skalniak、Lisa-Maria Köhler、Damian Muszak、Katarzyna Kurpiewska、Justyna Kalinowska-Tłuścik、Barbara Beck、Tad A. Holak、Alexander Dömling

  DOI：10.1016/j.ejmech.2019.111588

  日期：2019.11

  Intrinsically disordered proteins are an emerging class of proteins without a folded structure and currently disorder-based drug targeting remains a challenge. p53 is the principal regulator of cell division and growth whereas MDM2 consists its main negative regulator. The MDM2-p53 recognition is a dynamic and multistage process that amongst other, employs the dissociation of a transient alpha-helical N-terminal "lid" segment of MDM2 from the proximity of the p53-complementary interface. Several small molecule inhibitors have been reported to inhibit the formation of the p53-MDM2 complex with the vast majority mimicking the p53 residues Phe19, Trp23 and Leu26. Recently, we have described the transit from the 3-point to 4-point pharmacophore model stabilizing this intrinsically disordered N-terminus by increasing the binding affinity by a factor of 3. Therefore, we performed a thorough SAR analysis, including chiral separation of key compound which was evaluated by FP and 2D NMR. Finally, p53-specific anti-cancer activity towards p53-wild-type cancer cells was observed for several representative compounds. (C) 2019 Elsevier Masson SAS. All rights reserved.